labdesk
Catalyzing translational research efforts by
supporting preclinical and commercial clinical development

About Us

On May 27, 2020, the University of Michigan and healthcare investment firm Deerfield Management entered into an agreement to partner in the development and commercialization of therapeutic projects that hold promise in solving unmet medical needs. Deerfield has created a company named Great Lakes Discovery through which it will work with the University of Michigan, and committed up to $130 million over the next decade to invest in biomedical research at U-M with the aim of developing potentially life-saving drugs and disease treatments.

Projects selected by Great Lakes Discovery will be provided funding and operational support by Deerfield for a development plan aimed at achieving Investigational New Drug (IND) readiness. Successful projects that achieve IND-enabled status may be eligible for additional capital from Deerfield. Great Lakes Discovery, in exchange for funding, would receive an option to license intellectual property that is developed at U-M under this agreement. www.deerfield.com

Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy.

One of the nation’s top public universities, the University of Michigan has been a leader in research, learning and teaching for more than 200 years. U-M’s alumni body is one of the largest in the world and includes a U.S. president, scientists, actors, astronauts and inventors. The university, which also boasts a world-renowned intercollegiate athletics program, has been the site of many important events in U.S. history, including JFK’s announcement of the Peace Corps, LBJ’s “Great Society” speech, and the clinical trials of the Salk polio vaccine. The main campus in Ann Arbor comprises 19 schools and colleges; there are also regional campuses in Dearborn and Flint, and a nationally ranked health system, Michigan Medicine. In 2017, U-M celebrated its bicentennial, marking 200 years since its founding in the city of Detroit.

 

Joint Steering Committee

Kelly B. Sexton, Ph.D.
Alliance Ambassador

As associate vice president for research – technology transfer and innovation partnerships, Kelly works closely with the vice president for research as well as other leaders across the university to provide visionary and strategic leadership of UM’s innovation, business engagement and technology transfer activities, including the Office of Technology Transfer and the Business Engagement Center. In this role, she supports and encourages university-wide programs for intellectual property development, innovation, and engagement with business and venture communities in the region, across the nation, and around the globe.
Read More


As Alliance Ambassador for Great Lakes Discovery, Kelly works to ensure that the U-M therapeutics research community is aware of the resources available through Great Lakes Discovery, and that the alliance has the support of the U-M research and technology transfer infrastructure to ensure the successful translation of funded U-M projects.

Kelly holds a B.S. in Biochemistry and Molecular Biology from the University of Georgia and a Ph.D. in Molecular Pathology from the University of California, San Diego where she was supported by a fellowship from the California Breast Cancer Research Foundation. Kelly completed her postdoctoral studies at Stanford University where she was awarded a fellowship from the Susan G. Komen Breast Cancer Foundation. Kelly serves as co-chair of the U-M Roundtable on Innovation and Entrepreneurship, on the Advisory Board for the Detroit Chapter of Venture for America, and the Executive Committee of Ann Arbor SPARK.
Read Less

Kelly B. Sexton, Ph.D.

As associate vice president for research – technology transfer and innovation partnerships, Kelly works closely with the vice president for research as well as other leaders across the university to provide visionary and strategic leadership of UM’s innovation, business engagement and technology transfer activities, including the Office of Technology Transfer and the Business Engagement Center. In this role, she supports and encourages university-wide programs for intellectual property development, innovation, and engagement with business and venture communities in the region, across the nation, and around the globe.

As Alliance Ambassador for Great Lakes Discovery, Kelly works to ensure that the U-M therapeutics research community is aware of the resources available through Great Lakes Discovery, and that the alliance has the support of the U-M research and technology transfer infrastructure to ensure the successful translation of funded U-M projects.

Kelly holds a B.S. in Biochemistry and Molecular Biology from the University of Georgia and a Ph.D. in Molecular Pathology from the University of California, San Diego where she was supported by a fellowship from the California Breast Cancer Research Foundation. Kelly completed her postdoctoral studies at Stanford University where she was awarded a fellowship from the Susan G. Komen Breast Cancer Foundation. Kelly serves as co-chair of the U-M Roundtable on Innovation and Entrepreneurship, on the Advisory Board for the Detroit Chapter of Venture for America, and the Executive Committee of Ann Arbor SPARK.

Peter Toogood, Ph.D.
Director, Michigan Drug Discovery

Peter Toogood is Director of Michigan Drug Discovery, a campus-wide initiative to translate academic discoveries into new advances in medicine at the University of Michigan. He previously held the position of Senior Vice President for Chemistry and Chemical Biology at Lycera, an Ann Arbor based drug discovery company that he joined in 2007. In this role, he was a member of
Read More
the executive team and was a key scientific leader, helping to advance multiple compounds to the clinic. Prior to joining Lycera, Dr. Toogood worked at Parke-Davis/Pfizer in Ann Arbor, Michigan. His drug discovery experience encompasses the fields of immunology/inflammation, infectious diseases and cancer. He was a co-inventor of the cyclin-dependent kinase-4 inhibitor Ibrance® (palbociclib), for which he has been recognized by the American Chemical Society with both a Heroes in Chemistry Award (2016) and a Team Innovation Award (2017). Before joining Parke-Davis, Dr. Toogood served on the chemistry faculty of the University of Michigan in Ann Arbor, where he established an NIH and NSF funded research program in natural products total synthesis and chemical biology. He received his Ph.D. from Imperial College, London, working with Professor Steven V. Ley, and was a NATO postdoctoral fellow in the laboratory of Professor Jeremy R. Knowles at Harvard.
Read Less

Peter Toogood, Ph.D.

Peter Toogood is Director of Michigan Drug Discovery, a campus-wide initiative to translate academic discoveries into new advances in medicine at the University of Michigan. He previously held the position of Senior Vice President for Chemistry and Chemical Biology at Lycera, an Ann Arbor based drug discovery company that he joined in 2007. In this role, he was a member of the executive team and was a key scientific leader, helping to advance multiple compounds to the clinic. Prior to joining Lycera, Dr. Toogood worked at Parke-Davis/Pfizer in Ann Arbor, Michigan. His drug discovery experience encompasses the fields of immunology/inflammation, infectious diseases and cancer. He was a co-inventor of the cyclin-dependent kinase-4 inhibitor Ibrance® (palbociclib), for which he has been recognized by the American Chemical Society with both a Heroes in Chemistry Award (2016) and a Team Innovation Award (2017). Before joining Parke-Davis, Dr. Toogood served on the chemistry faculty of the University of Michigan in Ann Arbor, where he established an NIH and NSF funded research program in natural products total synthesis and chemical biology. He received his Ph.D. from Imperial College, London, working with Professor Steven V. Ley, and was a NATO postdoctoral fellow in the laboratory of Professor Jeremy R. Knowles at Harvard.

Steven L. Kunkel, Ph.D.
Peter A. Ward Distinguished University Professor

Dr. Steven Kunkel is the Peter A. Ward Distinguished University Professor, Endowed Professor of Pathology Research, and Chief Scientific Officer/Executive Vice-Dean for Research at the University of Michigan Medical School. He received his PhD at the University of Kansas in microbiology and did his post-doctoral training at the University of Connecticut Health Sciences. His areas of research have
Read More
centered on assessing molecular mechanisms of lung inflammation by investigating cytokine directed cell-to-cell communication circuits. A significant amount of this work helped to launch and define the field of chemokine biology. In his current administrative role, he oversees the entire spectrum of biomedical research from basic investigations to human subject/clinical trial research in the Medical School. His past administrative duties include: Interim Associate Vice President for Research, University of Michigan; Associate Dean for Interdisciplinary Studies, University of Michigan Horace H. Rackham Graduate School; Interim Dean, Horace H. Rackham Graduate School; and Interim Vice Provost for Academic Affairs. He has served on numerous National Institute of Health peer review study sections, organized a variety of international conferences on inflammation (Gordon and Keystone Conferences), is an associate editor for various professional scientific journals, and is a past recipient of an NIH MERIT Award. In addition, he is the chair of the Board of Scientific Counselors for the NIAID-NIH, a member of the American Society for Clinical Investigation, and a fellow of the American Association for the Advancement of Science.
Read Less

Steven L. Kunkel, Ph.D.

Dr. Steven Kunkel is the Peter A. Ward Distinguished University Professor, Endowed Professor of Pathology Research, and Chief Scientific Officer/Executive Vice-Dean for Research at the University of Michigan Medical School. He received his PhD at the University of Kansas in microbiology and did his post-doctoral training at the University of Connecticut Health Sciences. His areas of research have centered on assessing molecular mechanisms of lung inflammation by investigating cytokine directed cell-to-cell communication circuits. A significant amount of this work helped to launch and define the field of chemokine biology. In his current administrative role, he oversees the entire spectrum of biomedical research from basic investigations to human subject/clinical trial research in the Medical School. His past administrative duties include: Interim Associate Vice President for Research, University of Michigan; Associate Dean for Interdisciplinary Studies, University of Michigan Horace H. Rackham Graduate School; Interim Dean, Horace H. Rackham Graduate School; and Interim Vice Provost for Academic Affairs. He has served on numerous National Institute of Health peer review study sections, organized a variety of international conferences on inflammation (Gordon and Keystone Conferences), is an associate editor for various professional scientific journals, and is a past recipient of an NIH MERIT Award. In addition, he is the chair of the Board of Scientific Counselors for the NIAID-NIH, a member of the American Society for Clinical Investigation, and a fellow of the American Association for the Advancement of Science.

William Slattery
Partner

William Slattery is a Partner on the Therapeutics team and joined the Firm in 2000. Prior to Deerfield, Mr. Slattery was a senior healthcare analyst for 10 years at Amerindo Investment Advisors, where he oversaw biotechnology investments. He has held various positions in research including those at National Medical
Read More
Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. He holds an undergraduate degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.
Read Less

William Slattery

William Slattery is a Partner, in collaboration with the Deerfield Discovery and Development team and joined the Firm in 2000. Prior to Deerfield, Mr. Slattery was a senior healthcare analyst for ten years at Amerindo Investment Advisors, where he oversaw biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS. Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. He holds an undergraduate degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.

Scientific Collaboration Director

Seohee You, Ph.D.
Great Lakes Discovery Scientific Collaboration Director

Seohee You, Ph.D., brings a wealth of experience to Great Lakes Discovery, including over 10 years in academic and corporate therapeutic research and drug development. As Scientific Collaboration Director, she works closely with U-M faculty and with the broader Deerfield drug discovery and development team to ensure a robust pipeline of projects and to develop a research plan aimed to achieve Investigational New Drug (IND) readiness. She joins Great Lake Discovery from U-M Tech Transfer, where she worked with Life Sciences faculty to protect and commercialize intellectual property developed at U-M, while also significantly augmenting the research tools licensing program.
Read More


Before joining U-M Tech Transfer, she worked as a scientist at Janssen Pharmaceutical Companies of Johnson & Johnson. Through this position, she gained significant experience in various stages of both small and large molecule drug development. She co-led a Target Investigation and Target Validation project and advanced it through the Hit-to-Lead and Lead Optimization stages. She also served as a lead-preclinical scientist and successfully advanced a therapeutic agent to the NME (New Molecular Entity) nomination. Prior to this, she worked as a Senior Research Investigator and received her post-doctoral training at the Perelman School of Medicine at the University of Pennsylvania.

She holds a Ph. D. in Molecular & Cellular Biology from the University of Massachusetts and an M.S. in Biotechnology from Korea University. She is a registered dietitian with the Korean Ministry of Health and Welfare.
Read Less

Seohee You, Ph.D.

Seohee You, Ph.D., brings a wealth of experience to Great Lakes Discovery, including over 10 years in academic and corporate therapeutic research and drug development. As Scientific Collaboration Director, she works closely with U-M faculty and with the broader Deerfield drug discovery and development team to ensure a robust pipeline of projects and to develop a research plan aimed to achieve Investigational New Drug (IND) readiness. She joins Great Lake Discovery from U-M Tech Transfer, where she worked with Life Sciences faculty to protect and commercialize intellectual property developed at U-M, while also significantly augmenting the research tools licensing program.

Before joining U-M Tech Transfer, she worked as a scientist at Janssen Pharmaceutical Companies of Johnson & Johnson. Through this position, she gained significant experience in various stages of both small and large molecule drug development. She co-led a Target Investigation and Target Validation project and advanced it through the Hit-to-Lead and Lead Optimization stages. She also served as a lead-preclinical scientist and successfully advanced a therapeutic agent to the NME (New Molecular Entity) nomination. Prior to this, she worked as a Senior Research Investigator and received her post-doctoral training at the Perelman School of Medicine at the University of Pennsylvania.

She holds a Ph. D. in Molecular & Cellular Biology from the University of Massachusetts and an M.S. in Biotechnology from Korea University. She is a registered dietitian with the Korean Ministry of Health and Welfare.

 

News

Great Lakes Discovery to Facilitate University of Michigan Researcher to Pursue a Therapeutic Treatment for Systemic Inflammation
Deerfield Commits Up to $130 Million to Commercialize Drug Discovery at University of Michigan

Events

Past Events

Educational Programming brought to you by Cure, Deerfield’s Innovation Campus
Virtual Information Session
Wednesday October 21st at 3:30 PM ET
 

Proposal Submission



Proposal Sourcing
Go To LOI
arrow mobile-arrow
Science Review
Go To Full Proposal
arrow mobile-arrow
Full Proposal
Go To Investment Evaluation
arrow mobile-arrow
Investment Evaluation
Project
Funded

funded-ribbon

Access the Applicant Portal

Click here to access the application login page and/or create a profile. To contact Innovation Partnerships, please e-mail innovationpartnerships@umich.edu.

Frequently Asked Questions (FAQ)

Submission Disclosure
Great Lakes Discovery makes information about application process available to users who provide their personally identifiable information. If you do not wish to provide the information requested above, simply do not submit request to receive the application information. Please note that you are not required to provide your personal information or register to use this Site. By submitting your information, you are: (i) representing and warranting that you agree, and have the capacity to agree, to the Terms of Use and Privacy Policy (ii) providing your consent to receive electronic communications from Great Lakes Discovery, and (iii) representing that the information you have provided is complete and accurate. Each submission of information is for a single individual only. You understand that Great Lakes Discovery does not guarantee or warrant that the RFP application form it provides you be free of viruses or other destructive code. You are responsible for implementing sufficient procedures and checkpoints to satisfy your requirements The RFP application form is made available to you solely for your personal, non-commercial use, and you are prohibited from using, reproducing, modifying, transferring, exploiting, or distributing of any of the material provided to you for any other purpose. Great Lakes Discovery makes no representation that the requested material is appropriate or available for use in locations outside of the United States. If you choose to request the material from outside of the United States, you do so on your own initiative and are responsible for compliance with the applicable local laws.
 

Contact

Fields marked with an * are required.

Error sending form, please try again.

I agree to the Terms of Use and Privacy Policy.